Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S./Japan Free Trade Agreement Would Encourage Pharma Innovation, Lilly CEO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO Taurel argues in favor of an open market that would ease Japan-specific clinical trial requirements.

You may also be interested in...



Japanese Pharmas Need To Get More Global

Japanese firms need to change strategy to become competitive with U.S., European firms, biotech exec says in interview with "The Pink Sheet" DAILY during the BioInvestor Forum in San Francisco.

Japanese Pharmas Need To Get More Global

Japanese firms need to change strategy to become competitive with U.S., European firms, biotech exec says in interview with "The Pink Sheet" DAILY during the BioInvestor Forum in San Francisco.

Japanese Pharmas Need To Get More Global

Japanese pharmaceutical companies need to have a more global reach if they intend to be major players in an increasingly international biotech and pharma market, according to Berkeley, Calif.-based Plexxikon CEO Peter Hirth

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel